SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: arnie h who wrote (491)8/19/1997 1:20:00 AM
From: David Bogdanoff   of 2173
 
The explanation could simply be that uncontrolled factors such as insulin usage obfuscated the comparison between treated and control groups. Did the usage of insulin remain the same in both groups during the entire study? The report suggests it did not. How did this difference affect the primary criterion? How could was patient compliance during the whole study? Was it the same in the second 6 months as the first when a difference was detected? Why did 25% of the patients decline to continue on study drug and how appropriate is a 12 month study for a disease whose worst effects take a lifetime to appear? Diabetes is a very complex disease; many people have it and do not know it. It requires careful testing to detect the condition. It is not surprising that the effects of this drug may be difficult to detect.

David
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News